Use of the CANDIVAC cps. yeast plant lyophilisate in females with recurrent vulvovaginal candidiasis: clinical study results

Česká verzia

Authors: Vít Unzeitig ^1,2; Alexandra Stará ³; Jiří Dvořák ⁴; Jan Nový ⁵
Authors place of work: Centrum ambulantní gynekologie a primární péče Brno ¹; Gynekologicko-porodnická klinika MU a FN Brno ²; Gynekologická ambulance Praha ³; Gynekologická ambulance Kolín ⁴; Gynekologická ambulance Plzeň ⁵
Published in the journal: Prakt Gyn 2012; 16(2-4): 71-74
Category: Gynecology and Obstetrics: Original Article

Summary

The problem of the relapsing vulvovaginal candidiasis is not due to the infection with a new yeast plant, it lies in susceptibility to being infected by one’s own yeast plant. Help can be provided through immunomodulation by CANDIVAC cps. yeast lysates, which in a dose of 10 tablets per month for a period of six months brought a statistically significant reduction in the relapse occurrence as well as intensity of patients’ subjective complaints. There is no direct relation between the amount of yeast in the vagina, the quality of lactobacillary grading and the degree of seriousness of clinical symptoms.

Key words:
recurrent vulvovaginal candidiasis – immunomodulation therapy – lyofilisates – relaps of vulvovaginal candidiasis

Zdroje

1. Ledger WJ, Witkin SS. Vulvovaginal infections. London: Manson Publish 2007.

2. Mårdh PA, Rodrigues AG, Genç M et al. Facts and myths on recurrent vulvovaginal candidosis: a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. [Review]. International Journal of STD & AIDS 2002; 13(8): 522–539. [189 refs].

3. Unzeitig V, Kestřánek J, Špaček J. Podání transfer-faktoru (IMUNOR) u žen s chronickým vulvovaginálním diskomfortem: výsledky klinické studie. Prakt Gyn 2012; 16(1): 3–6.

4. Fidel PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. [Review] Clin Microbiol Rev 1996; 9(3): 335–348. [117 refs].

5. Šíma P. Bakteriální lyzáty jako imunostimulátory v prevenci onemocnění dýchacích cest. Tempus Medicorum 2011; 20(11 MF mediREPORT): 18–22.

6. Koukalová D, Bystroň J, Heřmanová Z, Ordeltová M, Szotkowska J. Imunologický profil pacientek s recidivujícími mykotickými kolpitidami před a po vakcinoterapii. Alergie 2001; 18(2): 117–119.